ReviewJournal of gastroenterology2013
Antigenic determinants of hepatitis E virus and vaccine-induced immunogenicity and efficacy.
Review in Journal of gastroenterology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 39 citations in OpenAlex.
- Stability Under Different Stress Treatments of a Virus-like Particle Vaccine Based on a Recombinant Hepatitis E Vaccine.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Spatial-temporal analysis of hepatitis E in Hainan Province, China (2013-2022): insights from four major hospitals.Frontiers in public health · 2024Article
- Pigs Immunized with the Virus-like Particle Vaccine Are Protected against the Hepatitis E-3 Virus.Vaccines · 2021Article
- High prevalence of anti-HEV antibodies among patients with immunosuppression and hepatic disorders in eastern Poland.Archives of medical science : AMS · 2021Article
- Oral Vaccination with Hepatitis E Virus Capsid Protein and Immunobiotic Bacterium-Like Particles Induce Intestinal and Systemic Immunity in Mice.Probiotics and antimicrobial proteins · 2020Article
- Functional epitopes on hepatitis E virions and recombinant capsids are highly conformation-dependent.Human vaccines & immunotherapeutics · 2020Article
- Hepatitis E virus: advances and challenges.Nature reviews. Gastroenterology & hepatology · 2018Review
- Development of new hepatitis E vaccines.Human vaccines & immunotherapeutics · 2018Review
- Phage-displayed peptides that mimic epitopes of hepatitis E virus capsid.Medical microbiology and immunology · 2017Article
- Knowledge Is Safety: The Time Is Ripe for Hepatitis E Virus Blood Donor Screening.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2016Article
- Hepatitis E virus: Current epidemiology and vaccine.Human vaccines & immunotherapeutics · 2016Review
- Functional assessment and structural basis of antibody binding to human papillomavirus capsid.Reviews in medical virology · 2016Review
- Hepatitis E virus: An ancient hidden enemy in Latin America.World journal of gastroenterology · 2016Review
- The development of a recombinant hepatitis E vaccine HEV 239.Human vaccines & immunotherapeutics · 2015Review
- Autochthonous Hepatitis E Virus Infection in Europe: A Matter of Concern for Public Health?Journal of clinical and translational hepatology · 2014Review
- Seroprevalence of Hepatitis E Virus Infection among Swine Farmers and the General Population in Rural Taiwan.PloS one · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There is emerging evidence for an under-recognized hepatitis E virus (HEV) as a human pathogen. Among different reasons for this neglect are the unsatisfactory performance and under-utilization of commercial HEV diagnostic kits; for instance, the number of anti-HEV IgM kits marketed in China is about one-fifth of that of hepatitis A kits. Over the last two decades, substantial progress has been achieved in furthering our knowledge on the HEV-specific immune responses, antigenic features of HEV virions, and development of serological assays and more recently prophylactic vaccines. This review will focus on presenting the evidence of the importance of HEV infection for certain cohorts such as pregnant women, the key antigenic determinants of the virus, and immunogenicity and clinical efficacy conferred by a newly developed prophylactic vaccine. Robust immunogenicity, greater than 195-fold and approximately 50-fold increase of anti-HEV IgG level in seronegative and seropositive vaccinees, respectively, as well as impressive clinical efficacy of this vaccine was demonstrated. The protection rate against the hepatitis E disease and the virus infection was shown to be 100% (95% CI 75-100) and 78% (95% CI 66-86), respectively.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.